Pier Capital LLC Buys 33,087 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR)

Pier Capital LLC boosted its position in shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 32.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 134,291 shares of the company's stock after buying an additional 33,087 shares during the period. Pier Capital LLC owned 0.23% of Structure Therapeutics worth $5,894,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the stock. Sandia Investment Management LP purchased a new stake in shares of Structure Therapeutics in the second quarter valued at approximately $39,000. Assetmark Inc. increased its stake in Structure Therapeutics by 120.0% during the third quarter. Assetmark Inc. now owns 1,318 shares of the company's stock worth $58,000 after acquiring an additional 719 shares during the last quarter. Quarry LP acquired a new stake in Structure Therapeutics during the second quarter worth about $79,000. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Structure Therapeutics by 60.1% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,784 shares of the company's stock worth $158,000 after buying an additional 1,420 shares during the period. Finally, Dearborn Partners LLC purchased a new stake in shares of Structure Therapeutics in the third quarter worth about $202,000. Institutional investors and hedge funds own 91.78% of the company's stock.

Structure Therapeutics Trading Up 6.8 %

GPCR stock traded up $2.11 during trading on Friday, reaching $33.35. 830,099 shares of the stock were exchanged, compared to its average volume of 790,990. Structure Therapeutics Inc. has a twelve month low of $26.61 and a twelve month high of $62.85. The company has a market capitalization of $1.91 billion, a P/E ratio of -45.07 and a beta of -3.41. The stock has a 50 day simple moving average of $37.29 and a 200-day simple moving average of $39.35.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. Cantor Fitzgerald reissued an "overweight" rating and issued a $65.00 price target on shares of Structure Therapeutics in a report on Monday, September 23rd. Morgan Stanley initiated coverage on Structure Therapeutics in a research report on Monday, September 23rd. They issued an "overweight" rating and a $118.00 target price on the stock. Finally, HC Wainwright began coverage on Structure Therapeutics in a research report on Wednesday. They issued a "buy" rating and a $80.00 target price on the stock. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $85.67.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.